-+ 0.00%
-+ 0.00%
-+ 0.00%

ImmuCell appoints Gilles Guillemette, Anthony DiMarco to board

PUBT·04/13/2026 20:38:22
Listen to the news
ImmuCell appoints Gilles Guillemette, Anthony DiMarco to board
  • ImmuCell appointed Gilles Guillemette and Anthony DiMarco to board effective April 15, 2026.
  • Guillemette brings 30+ years in animal health therapeutics, including executive roles at Elanco and Bayer, with current role as operating partner at Archimed.
  • DiMarco brings four decades in biologics, including 21 years as VP of R&D and Global Manufacturing at IDEXX, following scientific roles at Abbott Laboratories.
  • Board will shift to seven members, including six independent directors and CEO, with a new Strategy and Technology Committee chaired by Guillemette.
  • Directors Bryan Gathagan, Michael Brigham, and Bobbi Brockmann will retire effective April 15, 2026; Timothy Fiori will retire after 2026 annual meeting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmuCell Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604131638PRIMZONEFULLFEED9688895) on April 13, 2026, and is solely responsible for the information contained therein.